natgillin/translations-raw huggingface dataset:
Abseamed is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. 
Abseamed je indiciran u odraslih koji primaju kemoterapiju zbog solidnih tumora, malignog limfoma ili multiplog mijeloma, te kod kojih postoji rizik od transfuzije prema procjeni njihovog općeg stanja (npr. kardiovaskularni status, anemija koja je prisutna na početku kemoterapije), za liječenje anemije i smanjenje potrebe za transfuzijom.
• Before use, leave the Abseamed syringe to stand until it reaches room temperature. 
• Prije primjene, ostavite štrcaljku Abseameda izvan hladnjaka dok ne postigne sobnu temperaturu.
• If you are having dialysis treatment when you begin treatment with Abseamed, your dialysis regime may need to be adjusted. 
• Ako u vrijeme početka liječenja Abseamedom idete na dijalizu, možda će biti potrebno prilagoditi raspored dijalize.
Abseamed is presented as a clear, colourless solution for injection in a pre-filled syringe. 
Abseamed je dostupan u obliku bistre, bezbojne otopine za injekciju u napunjenoj štrcaljki.
If you develop a serious rash or another of these skin symptoms, stop taking Abseamed and contact your doctor or seek medical attention immediately. 
U slučaju nastanka ozbiljnog osipa ili drugih kožnih simptoma, prestanite uzimati lijek Abseamed i odmah se obratite svojem liječniku ili potražite medicinsku pomoć.
Abseamed is prescribed to stimulate your bone marrow to produce more red blood cells. 
Abseamed se propisuje za poticanje koštane srži na stvaranje više crvenih krvnih stanica.
In patients with a poor haemoglobin response to Abseamed, alternative explanations for the poor response should be considered (see section 4.4 and 5.1). 
U bolesnika sa slabim odgovorom hemoglobina na Abseamed, potrebno je razmotriti druga moguća objašnjenja za slab odgovor (vidjeti dio 4.4 i 5.1).
Before use, leave the Abseamed syringe to stand until it reaches room temperature. 
Prije primjene, ostavite štrcaljku Abseameda izvan hladnjaka dok ne postigne sobnu temperaturu.
Abseamed contains sodium 
Abseamed sadrži natrij
Abseamed is used in moderately anaemic adults about to have major orthopaedic surgery (for example hip or knee replacement operations), to reduce the potential need for blood transfusions. 
Abseamed se primjenjuje u odraslih osoba s umjerenom anemijom kojima predstoji veliki ortopedski kirurški zahvat (na primjer, operacija zamjene kuka ili koljena), radi smanjivanja moguće potrebe za transfuzijama krvi.
Abseamed is not approved in the management of anaemia associated with hepatitis C. 
Abseamed nije odobren za liječenje anemije povezane s hepatitisom C.
Your doctor will decide how Abseamed will be injected. 
Liječnik će odlučiti kako će se davati injekcija Abseamed.
Side effects from an overdose of Abseamed are unlikely. 
Nuspojave zbog predoziranja Abseamedom su malo vjerojatne.
Abseamed is used to treat anaemia in adults with a bone marrow disorder that causes a severe disruption in the creation of blood cells (myelodysplastic syndromes). 
Abseamed se primjenjuje za liječenje anemije u odraslih osoba s poremećajem koštane srži koji uzrokuje teške poremećaje u stvaranju krvnih stanica (mijelodisplastični sindromi).
Abseamed is used to treat anaemia in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma (bone marrow cancer) who may have a need for a blood transfusion. 
Abseamed se primjenjuje za liječenje anemije u odraslih koji primaju kemoterapiju zbog solidnog tumora, zloćudnog limfoma ili multiplog mijeloma (rak koštane srži) i kod kojih bi mogla postojati potreba za transfuzijom krvi.
Your Abseamed dose and frequency of administration may be further adjusted to maintain your response to treatment. 
Dodatno Vam može prilagoditi dozu i učestalost primjene Abseameda kako bi se održao odgovor na liječenje.
In cases where there is a medical need to shorten the lead time before surgery to less than three weeks, Abseamed 300 IU/kg should be administered subcutaneously daily for 10 consecutive days prior to surgery, on the day of surgery and for four days immediately thereafter. 
U slučajevima u kojima je iz medicinskih razloga potrebno skratiti razdoblje do kirurškog zahvata na manje od tri tjedna, treba supkutano primijeniti 300 IU/kg Abseameda dnevno tijekom 10 uzastopnih dana prije kirurškog zahvata, na sam dan kirurškog zahvata i tijekom četiri dana nakon kirurškog zahvata.
Only take one dose of Abseamed from each syringe discarding unwanted solution before injection. 
Uzmite samo jednu dozu lijeka Abseamed iz svake štrcaljke i nepotrebnu otopinu bacite prije primjene injekcije.
How to store Abseamed 
Kako primjenjivati Abseamed
Abseamed is used to treat symptomatic anaemia caused by kidney disease: 
Abseamed se primjenjuje za liječenje simptomatske anemije prouzročene bolešću bubrega:
Some people, depending on why they need Abseamed treatment, may later learn how to inject themselves under the skin: see Instructions on how to inject Abseamed yourself at the end of the leaflet. 
Abseamedom, mogu kasnije naučiti kako da same sebi daju injekciju pod kožu: vidjeti Upute za samostalnu primjenu injekcije Abseamed na kraju ove upute.
“Instructions on how to inject Abseamed yourself” can be found at the end of the package leaflet. 
„Upute za samostalnu primjenu injekcije Abseamed” mogu se pronaći na kraju upute o lijeku.
If the haemoglobin level reaches 15 g/dL (9.38 mmol/L), or higher, during the preoperative period, administration of Abseamed should be stopped and further dosages should not be administered. 
Ako tijekom predoperacijskog razdoblja razina hemoglobina postigne vrijednost od 15 g/dl (9,38 mmol/l) ili više, primjenu Abseameda treba prekinuti i više ne treba primijeniti dodatne doze.
Patients should be monitored closely to ensure that the lowest approved dose of Abseamed is used to provide adequate control of anaemia and of the symptoms of anaemia. 
Bolesnike treba pažljivo pratiti kako bi se osigurala primjena najniže odobrene doze Abseameda koja pruža odgovarajuću kontrolu anemije i simptoma anemije.
If you are a patient with chronic renal failure, and particularly if you do not respond properly to Abseamed, your doctor will check your dose of Abseamed because repeatedly increasing your dose of Abseamed if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death. 
Abseamedom na primjeren način, Vaš će liječnik provjeriti Vašu dozu Abseameda jer opetovano povećavanje doze Abseameda ako ne odgovarate na liječenje, može povećati rizik od tegoba sa srcem ili krvnim žilama te može povećati rizik od srčanog udara, moždanog udara i smrti.
Take special care with Abseamed: 
Potreban je poseban oprez pri primjeni lijeka Abseamed:
Where intravenous access is not readily available Abseamed may be administered subcutaneously. 
Kada intavenski pristup nije lako dostupan, Abseamed se može primijeniti supkutano.
The effect of epoetin alfa in facilitating autologous blood donation in patients with low haematocrits (≤ 39% and no underlying anaemia due to iron deficiency) scheduled for major orthopaedic surgery was evaluated in a double-blind, placebo-controlled study conducted in 204 patients, and a single-blind placebo controlled study in 55 patients. 
(≤ 39 % i bez podležeće anemije zbog nedostatka željeza) predviđenih za veliki ortopedski kirurški zahvat ocijenjen je u dvostruko slijepom, placebom kontroliranom ispitivanju provedenom na 204 bolesnika i jednostruko slijepom, placebom kontroliranom ispitivanju na 55 bolesnika.
Caution should be exercised with escalation of Abseamed doses in patients with chronic renal failure since high cumulative epoetin doses may be associated with an increased risk of mortality, serious cardiovascular and cerebrovascular events. 
Potreban je oprez pri povećavanju doza Abseameda u bolesnika s kroničnim zatajenjem bubrega, budući da visoke kumulativne doze epoetina mogu biti povezane s povećanim rizikom od smrtnosti,
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe 
Abseamed 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 2000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 3000 IU/0,3 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 4000 IU/0,4 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 6000 IU/0,6 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 7000 IU/0,7 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 8000 IU/0,8 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 9000 IU/0,9 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 20 000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 30 000 IU/0,75 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 40 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
Package leaflet: Information for the patient Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa Read all of this leaflet carefully before you start using this medicine because it contains important information for you. 
Abseamed 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 2000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 3000 IU/0,3 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 4000 IU/0,4 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 6000 IU/0,6 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 7000 IU/0,7 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 8000 IU/0,8 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 9000 IU/0,9 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 20 000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 30 000 IU/0,75 ml otopina za injekciju u napunjenoj štrcaljki Abseamed 40 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki epoetin alfa
Abseamed should be administered in order to increase haemoglobin to not greater than 11 g/dL (6.8 mmol/L). 
Abseamed treba primjenjivati kako bi se razina hemoglobina povisila do najviše 11 g/dl (6,8 mmol/l).
Instructions on how to inject yourself with Abseamed can be found at the end of this leaflet. 
Upute za samostalnu primjenu injekcije Abseamed nalaze se na kraju ove upute.
Abseamed is indicated for the treatment of symptomatic anaemia (haemoglobin concentration of ≤ 10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (< 200 mU/mL). 
u odraslih s primarnim mijelodisplastičnim sindromom (MDS) niskog ili srednjeg-1 rizika koji imaju niski serumski eritropoetin (< 200 mU/ml).
Abseamed contains less than 1 mmol sodium (23 mg) per dose that is to say essentially “sodium free”. 
Abseamed sadrži manje od 1 mmol natrija (23 mg) po dozi, tj. zanemarive količine natrija.
Caution should be exercised with escalation of Abseamed doses in patients with chronic renal failure. 
Potreban je oprez pri povećavanju doza Abseameda u bolesnika s kroničnim zatajenjem bubrega.
Do not use Abseamed: 
Nemojte primjenjivati Abseamed:
Abseamed should be administered in order to increase haemoglobin to not greater than 12 g/dL (7.5 mmol/L). 
Abseamed treba primjenjivati kako bi se hemoglobin povisio na razinu koja nije viša od 12 g/dl (7,5 mmol/l).
If the haemoglobin concentration is increasing by more than 2 g/dL (1.25 mmol/L) per month, or if the haemoglobin concentration level exceeds 12 g/dL (7.5 mmol/L), reduce the Abseamed dose by about 25 to 50%. 
Ako se koncentracija hemoglobina povećava za više od 2 g/dl (1,25 mmol/l) na mjesec, ili koncentracija hemoglobina prijeđe 12 g/dl (7,5 mmol/l), smanjite dozu Abseameda za oko 25 do 50 %.
Abseamed should be administered to patients with anaemia (e.g. haemoglobin concentration ≤ 10 g/dL (6.2 mmol/L)). 
Abseamed treba primijeniti u bolesnika s anemijom (npr. koncentracija hemoglobina ≤ 10 g/dl (6,2 mmol/l)).
Abseamed should be administered to patients with symptomatic anaemia (e.g. haemoglobin concentration ≤ 10 g/dL (6.2 mmol/L)). 
Lijek Abseamed treba primijeniti u bolesnika sa simptomatskom anemijom (npr. koncentracija hemoglobina ≤ 10 g/dl (6,2 mmol/l)).
If the haemoglobin is rising by more than 2 g/dL (1.25 mmol/L) per month, or if the sustained haemoglobin exceeds 12 g/dL (7.5 mmol/L) reduce the Abseamed dose by 25%. 
Ako razina hemoglobina raste za više od 2 g/dl (1,25 mmol/l) na mjesec ili ako razina hemoglobina kontinuirano prelazi 12 g/dl (7,5 mmol/l) smanjite dozu Abseameda za 25 %.
If the haemoglobin exceeds 13 g/dL (8.1 mmol/L), discontinue therapy until it falls below 12 g/dL (7.5 mmol/L) and then reinstitute Abseamed therapy at a dose 25% below the previous dose. 
Ako razina hemoglobina prijeđe 13 g/dl (8,1 mmol/l), prekinite terapiju sve dok razina hemoglobina ne padne ispod 12 g/dl (7,5 mmol/l) i potom ponovno uvedite terapiju Abseamedom u dozi koja je 25 % manja od prethodne doze.
If the haemoglobin concentration level exceeds 13 g/dL (8.1 mmol/L), discontinue therapy until it falls below 12 g/dL (7.5 mmol/L) and then reinitiate Abseamed therapy at a dose 25% below the previous dose. 
Ako koncentracija hemoglobina prelazi 13 g/dl (8,1 mmol/l), prekinite terapiju sve dok vrijednost ne padne ispod 12 g/dl (7,5 mmol/l) i zatim ponovno uvedite terapiju Abseamedom u dozi koja je 25 % niža od prethodne.
In paediatric patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Abseamed by the intravenous route is preferable. 
U pedijatrijskih bolesnika s kroničnim zatajenjem bubrega u kojih je rutinski dostupan intravenski pristup (bolesnici na hemodijalizi) preferira se primjena lijeka Abseamed intravenskim putem.
Abseamed should not be used and discarded - if the liquid is coloured or you can see particles floating in it, - if the seal is broken, - if you know, or think that it may have been accidentally frozen, or - if there has been a refrigerator failure. 
6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijekom Abseamed se ne smije primijeniti i mora se baciti - ako je tekućina obojena ili se u njoj vide plutajuće čestice, - ako je pakiranje oštećeno,
Only take one dose of Abseamed from each syringe. 
Iz jedne štrcaljke uzmite samo jednu dozu lijeka Abseamed.
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa 
Abseamed 30 000 IU/0,75 ml otopina za injekciju u napunjenoj štrcaljki epoetin alfa
In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Abseamed by the intravenous route is preferable. 
U bolesnika s kroničnim zatajenjem bubrega u kojih je rutinski dostupan intravenski pristup (bolesnici na hemodijalizi) preferira se primjena lijeka Abseamed intravenskim putem.
Only one dose of Abseamed from each syringe should be taken. 
Jednom štrcaljkom smije se primijeniti samo jedna doza lijeka Abseamed.
• Keep this medicine out of the sight and reach of children. 
Kako čuvati Abseamed • Lijek čuvajte izvan pogleda i dohvata djece.
INFORMATION IN BRAILLE Abseamed 30,000 IU/0.75 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 30 000 IU/0,75 ml
INFORMATION IN BRAILLE Abseamed 8,000 IU/0.8 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 8000 IU/0,8 ml
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Each syringe contains 0.8 mL of solution for injection. 
Abseamed 8000 IU/0,8 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 0,8 ml otopine za injekciju.
Abseamed is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): 
Abseamed je indiciran za liječenje simptomatske anemije povezane s kroničnim zatajenjem bubrega
INFORMATION IN BRAILLE Abseamed 7,000 IU/0.7 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 7000 IU/0,7 ml
INFORMATION IN BRAILLE Abseamed 9,000 IU/0.9 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 9000 IU/0,9 ml
INFORMATION IN BRAILLE Abseamed 40,000 IU/1 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 40 000 IU/1 ml
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Each syringe contains 0.75 mL of solution for injection. 
Abseamed 30 000 IU/0,75 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 0,75 ml otopine za injekciju.
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Each syringe contains 0.9 mL of solution for injection. 
Abseamed 9000 IU/0,9 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 0,9 ml otopine za injekciju.
INFORMATION IN BRAILLE Abseamed 6,000 IU/0.6 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 6000 IU/0,6 ml
Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Each syringe contains 0.7 mL of solution for injection. 
Abseamed 7000 IU/0,7 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 0,7 ml otopine za injekciju.
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe EU/1/07/412/013 
Abseamed 8000 IU/0,8 ml otopina za injekciju u napunjenoj štrcaljki EU/1/07/412/013
INFORMATION IN BRAILLE Abseamed 20,000 IU/0.5 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 20 000 IU/0,5 ml
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 9,000 IU/0.9 mL injection 
NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Abseamed 9000 IU/0,9 ml injekcija epoetin alfa i.v./s.c.
INFORMATION IN BRAILLE Abseamed 4,000 IU/0.4 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 4000 IU/0,4 ml
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Each syringe contains 0.4 mL of solution for injection. 
Abseamed 4000 IU/0,4 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 0,4 ml otopine za injekciju.
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe EU/1/07/412/023 
Abseamed 30 000 IU/0,75 ml otopina za injekciju u napunjenoj štrcaljki EU/1/07/412/023
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe 
Abseamed 8000 IU/0,8 ml otopina za injekciju u napunjenoj štrcaljki epoetin alfa
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 7,000 IU/0.7 mL injection 
NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Abseamed 7000 IU/0,7 ml injekcija epoetin alfa i.v./s.c.
INFORMATION IN BRAILLE Abseamed 5,000 IU/0.5 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 5000 IU/0,5 ml
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 30,000 IU/0.75 mL injection 
NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Abseamed 30 000 IU/0,75 ml injekcija epoetin alfa i.v./s.c.
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Each mL of solution contains 2,000 IU of epoetin alfa* corresponding to 16.8 micrograms per mL 
Abseamed 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Jedan ml otopine sadrži 2000 IU epoetina alfa*, što odgovara 16,8 mikrograma po ml.
Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL 
Abseamed 40 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Jedan ml otopine sadrži 40 000 IU epoetina alfa*, što odgovara 336,0 mikrograma po ml.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 8,000 IU/0.8 mL injection 
NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Abseamed 8000 IU/0,8 ml injekcija epoetin alfa i.v./s.c.
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/009 
Abseamed 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/07/412/009
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe 
Abseamed 9000 IU/0,9 ml otopina za injekciju u napunjenoj štrcaljki epoetin alfa
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL 
Abseamed 30 000 IU/0,75 ml otopina za injekciju u napunjenoj štrcaljki Jedan ml otopine sadrži 40 000 IU epoetina alfa*, što odgovara 336,0 mikrograma po ml.
Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Each syringe contains 0.6 mL of solution for injection. 
Abseamed 6000 IU/0,6 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 0,6 ml otopine za injekciju.
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL 
Abseamed 20 000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Jedan ml otopine sadrži 40 000 IU epoetina alfa*, što odgovara 336,0 mikrograma po ml.
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL 
Abseamed 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Jedan ml otopine sadrži 10 000 IU epoetina alfa*, što odgovara 84,0 mikrograma po ml.
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 2,000 IU of epoetin alfa* corresponding to 16.8 micrograms per mL 
Abseamed 2000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Jedan ml otopine sadrži 2000 IU epoetina alfa*, što odgovara 16,8 mikrograma po ml.
INFORMATION IN BRAILLE Abseamed 10,000 IU/1 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 10 000 IU/1 ml
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/021 
Abseamed 20 000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/07/412/021
INFORMATION IN BRAILLE Abseamed 3,000 IU/0.3 mL 
16. PODACI NA BRAILLEOVOM PISMU Abseamed 3000 IU/0,3 ml
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 4,000 IU/0.4 mL injection 
NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Abseamed 4000 IU/0,4 ml injekcija epoetin alfa i.v./s.c.
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe EU/1/07/412/019 
Abseamed 9000 IU/0,9 ml otopina za injekciju u napunjenoj štrcaljki EU/1/07/412/019